InvestorsHub Logo
Followers 33
Posts 2635
Boards Moderated 1
Alias Born 06/13/2007

Re: SakartveloChan post# 50345

Wednesday, 01/10/2018 3:55:57 PM

Wednesday, January 10, 2018 3:55:57 PM

Post# of 73679
The patents are underestimated, the issue is there is no money in the biologics division and no revenue only debt from cancer research. It will take a VC to drum up any interest with the patents or start up the cancer research again. The pain management division can barely sustain operations without selling shares let alone further anything in the biologics side.